Pfizer says its JAK drug topped Dupixent in a head-to-head eczema test — but you'll have to wait on the data
Just a few hours after Sanofi and Regeneron unveiled a new slate of data for Dupixent in children with eczema, Pfizer released its own …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
